Analyzing Polyrizon (NASDAQ:PLRZ) & Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Curis and Polyrizon, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1	0	1	0	2.00
Polyrizon	1	0	0	0	1.00

Curis presently has a consensus target price of $17.00, indicating a potential upside of 2,737.12%. Given Curis’ stronger consensus rating and higher probable upside, equities analysts plainly believe Curis is more favorable than Polyrizon.

Profitability

This table compares Curis and Polyrizon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-119.73%
Polyrizon	N/A	N/A	N/A

Valuation and Earnings

This table compares Curis and Polyrizon”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44 million	2.54	-$7.58 million	($1.19)	-0.50
Polyrizon	N/A	N/A	-$3.34 million	N/A	N/A

Polyrizon has lower revenue, but higher earnings than Curis.

Institutional & Insider Ownership

30.0% of Curis shares are held by institutional investors. 5.4% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Curis has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500. Comparatively, Polyrizon has a beta of -4.6, indicating that its share price is 560% less volatile than the S&P 500.

Summary

Curis beats Polyrizon on 7 of the 10 factors compared between the two stocks.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.